Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Published:2014-03 Issue:3 Volume:15 Page:343-352
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Davies Andrew,Merli Francesco,Mihaljevic Biljana,Siritanaratkul Noppadol,Solal-Céligny Phillippe,Barrett Martin,Berge Claude,Bittner Beate,Boehnke Axel,McIntyre Christine,MacDonald David

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

2. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol,2008

3. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 Study;Hochster;J Clin Oncol,2009

4. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial;Salles;Lancet,2011

5. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study;Van Oers;J Clin Oncol,2010

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution;Molecular Pharmaceutics;2024-09-03

2. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

3. Navigating the complexities of drug development for inflammatory bowel disease;Nature Reviews Drug Discovery;2024-05-22

4. A compartment model for subcutaneous injection of monoclonal antibodies;International Journal of Pharmaceutics;2024-01